Last reviewed · How we verify

Zhen-Hai Lu — Portfolio Competitive Intelligence Brief

Zhen-Hai Lu pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Capecitabine monotherapy Capecitabine monotherapy phase 3 Fluoropyrimidine antimetabolite Thymidylate synthase Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Chinese PLA General Hospital · 1 shared drug class
  3. Federation Francophone de Cancerologie Digestive · 1 shared drug class
  4. Hoffmann-La Roche · 1 shared drug class
  5. Japan Clinical Oncology Group · 1 shared drug class
  6. Jiangxi Provincial Cancer Hospital · 1 shared drug class
  7. National Cancer Center, Korea · 1 shared drug class
  8. Peter MacCallum Cancer Centre, Australia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zhen-Hai Lu:

Cite this brief

Drug Landscape (2026). Zhen-Hai Lu — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhen-hai-lu. Accessed 2026-06-09.

Related